




(D2AAK4), a Multi-Target Ligand of Aminergic
GPCRs, as a Potential Antipsychotic
Agnieszka A. Kaczor 1,2,* , Katarzyna M. Targowska-Duda 3, Andrea G. Silva 4 ,
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4-carboxamide (D2AAK4) is a multitarget ligand of aminergic G protein-coupled receptors (GPCRs)
identified in structure-based virtual screening. Here we present detailed in vitro, in silico and in vivo
investigations of this virtual hit. D2AAK4 has an atypical antipsychotic profile and low affinity
to off-targets. It interacts with aminergic GPCRs, forming an electrostatic interaction between its
protonatable nitrogen atom and the conserved Asp 3.32 of the receptors. At the dose of 100 mg/kg
D2AAK4 decreases amphetamine-induced hyperactivity predictive of antipsychotic activity, improves
memory consolidation in passive avoidance test and has anxiogenic properties in elevated plus maze
test (EPM). Further optimization of the virtual hit D2AAK4 will be aimed to balance its multitarget
profile and to obtain analogs with anxiolytic activity.
Keywords: antipsychotics; behavioral studies; drug design; in vitro studies; molecular modeling;
schizophrenia
1. Introduction
Schizophrenia is a severe and chronic mental illness with high prevalence (appearing in about
0.5%–1% of the population) [1], and it remains among the 20 leading causes of health loss in terms of
years lived with disability (YLDs) from 161 causes analyzed worldwide [2]. Symptoms of schizophrenia
generally emerge during adolescence or early adulthood and are grouped into positive, negative
and cognitive symptoms. Psychotic or positive symptoms include severe thought disorganization
like hallucinations (often auditory hallucinations) and delusions (which often involve persecution
or megalomania). Deficit or negative symptoms include affect flattening, poverty of speech, social
withdrawal and anhedonia. Cognitive symptoms concern memory and concentration disturbances.
The pathomechanism of schizophrenia remains unclear, but it is generally agreed that it involves
many neurotransmitter systems. The central hypothesis of schizophrenia is still the dopaminergic
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hypothesis, which is complemented by the glutamatergic hypothesis [3–5]. Other neurotransmitter
systems, in particular serotonin and γ-aminobutyric acid (GABA), as well as cholinergic, cannabinoid
and opioid systems, are also important in the pathogenesis of schizophrenia.
Antipsychotic drugs are crucial for the comprehensive approach to the treatment of schizophrenia
as they are able to supply significant symptom relief and a broad psychosocial recovery for patients.
Although modern antipsychotics do not cure schizophrenia, these drugs control the intensity of the
symptoms, diminish exacerbations of the illness and decrease the risk of relapse [6]. Nevertheless,
current antipsychotic drug therapies are associated with significant side effects and medical morbidity
burdens that may hinder progress toward treatment goals.
The drugs used in schizophrenia are divided into typical (first generation) and atypical
antipsychotics, and among the latter, there are drugs classified as second and third generation.
This classification groups together drugs rather heterogeneous in their clinical efficacy and tolerability
as well as pharmacological profile [7]. However, it takes into account some fundamental mechanisms of
action that are considered essential for the antipsychotic efficacy of currently approved antipsychotics.
Both first- and second-generation antipsychotics present a dopamine D2 antagonist component in their
pharmacological profile, which, in the case of second-generation atypical antipsychotics, can be of
weak affinity (e.g., clozapine, quetiapine) and it is complemented with a serotonin 5-HT2A antagonism
of relative higher affinity. Chronic blockade of striatal D2 receptors and high occupancy of the receptor
in the striatum have been related to extrapyramidal symptoms that constitute the more severe adverse
effect of typical antipsychotics, whereas the combined D2/5-HT2A antagonism that characterizes
second-generation drugs would help to avoid those serious side effects of typical neuroleptics, i.e.,
motor disorders from the extrapyramidal system. Finally, drugs such as aripiprazole, brexpiprazole
and cariprazine, are classified as third-generation antipsychotics, and they are considered partial or
biased agonists of dopamine D2 receptor. Still, atypical antipsychotics modulate a broader panel of
targets that exceed those mentioned above, constituting a prototypical example of multitarget therapies,
and their complex modulation of neurotransmitter receptors beyond D2 and 5-HT2A, together with
additional actions on neuronal plasticity and neurogenesis, in the long term might contribute to clinical
efficacy [7]. In spite of the broad pharmacotherapeutic arsenal currently approved, there is still no
antipsychotic medication efficacious against all the different symptoms of schizophrenia, and an
improved safety profile of these drugs is still highly desirable.
The change in the paradigm of “one disease, one gene, one goal, one drug” prevailing over the
last 20 years in the chemistry of drugs is shifting the therapeutic process towards drugs affecting many
molecular targets, i.e., multitarget drugs that have become a hope in the treatment of diseases with
complex pathomechanism such as schizophrenia. Multitarget drugs work comprehensively because
they take into account the complexity of the molecular mechanism of the disease and give a better
chance to modify or cure the disease process. In addition, a single multitarget drug offers less risk of
drug–drug interactions, which is a significant advantage over combination therapies. Administration of
one single drug is more convenient, reducing the risk of incorrect dosage or medication noncompliance
of more complex dosage regimens. Another benefit would be the eventually fewer side effects [8].
The aim of this work was to use molecular modeling, in vitro assays and behavioral studies
to evaluate the new compound N-(2-hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol
-1-yl)propyl]piperidine-4-carboxamide (D2AAK4), Figure 1 which was identified in structure-based
virtual screening aimed to search for novel ligands of dopamine D2 receptor [9]. The virtual screening
was performed using dopamine D2 receptor complexes with chlorprothixene and olanzapine obtained
by induced fit docking approach. As the olanzapine is an atypical antipsychotic, the binding pocket
was modified to prioritize compounds with the atypical profile. It should be stressed, however, that in
order to identify atypical antipsychotics with higher affinity to serotonin 5-HT1A and 5-HT2A receptors
than to dopamine D2 receptors, serotonin receptors should be also considered during the virtual
screening campaign, not to limit the study. This will be the aim of our future work. Nevertheless,
D2AAK4, identified in the previous virtual screening experiment, is a multitarget ligand with affinity
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to D2 receptor, additional affinity for D1, D3, 5-HT2A and 5-HT7 receptors and with low affinity for
potential off-targets M1 and H1 receptors. We used here a combination of in vitro, in silico (homology
modeling, molecular docking, molecular dynamics) and in vivo approaches (to assess antipsychotic,
procognitive and anxiolytic properties of the compound) to characterize the virtual hit D2AAK4 before
its future rational optimization as lead structure for a potential antipsychotic.
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2. Materials and Methods
2.1. In Vitro Studies
2.1.1. Receptor Binding Assays
Radioligand binding assays were performed on cell membrane preparations from cell lines
stably expressing the human cloned receptors. Chinese hamster ovary K1 (CHO-K1) cell lines stably
expressing human D2S, 5-HT2A or H1 receptors and human embryonic kidney 293 (HEK293) cell
lines stably expressing human 5-HT1A or 5-HT7(a) receptors were in-house available [9–11], whereas
CHO-K1 cell lines stably expressing human D1 or D3 receptors (Perkin Elmer, Waltham, MA, USA) and
Chem-1 cell line stably expressing human M1 receptor (Millipore, Merck KGaA, Darmstadt, Germany)
were commercially available. Experimental conditions for binding assays at D1, D2, D3, 5-HT1A and
5-HT2A receptors have been previously reported [12]. 0.7 nM [3H]-SCH23390, 2 nM [3H]-SB269970
(5-HT7), 2 nM [3H]-Pyrilamine (H1) and 2 nM [3H]-Pirenzepine (M1) were employed as radioligands.
Nonspecific binding was assessed in the presence of 25 µM clozapine (5-HT7), 10 µM triprolidine (H1)
and 200 µM pirenzepine (M1). D2AAK4 was initially evaluated at the single concentration (10 µM) in
competition radioligand binding assays at all the different receptors studied, and at those receptors
at which 10 µM compound achieved >40% inhibition of specific radioligand binding, competition
binding curves of D2AAK4 were constructed using six or seven different concentrations of compound,
starting at 0.1 nM or 1 nM till full displacement or a maximal concentration (100 µM or 300 µM) was
reached. Affinity (equilibrium dissociation constant (Ki) and pKi (−logKi)) values were calculated
as previously reported [13]. Affinity values of reference compounds that were assayed in parallel to
D2AAK4 as internal controls in the binding assays are given in Supplementary Figure S1 (legend).
2.1.2. Functional Assay at D2 R ceptors
The efficacy of D2AAK4 as agonist or antagonist of D2 receptors was evaluated in functional
assays of cAMP signaling in the CHO-K1 cell line stably expressing the human D2S receptor employed
in radioligand binding assays, following a protocol already described [9,12]. Compound was initially
assessed at 10 µM concentration either as agonist or as antagonist of 10 µM dopamine response.
Dopamine (10 nM–1 mM) was used as reference agonist in these assays. The antagonist effect of
D2AAK4 on 10 µ dopamine response was further investigated in concentration-response curves
constructed using seven concentrations of D2AAK4 ranging from 0.1 nM to 100 µM. Haloperidol
(0.1 nM–10 µM) was used as reference antagonist in these assays.
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2.1.3. Functional Assay at 5-HT2A Receptors
The efficacy of D2AAK4 as agonist or antagonist of 5-HT2A receptors was evaluated in functional
assays of inositol phosphate (IP) production in the CHO-K1 cell line stably expressing the human
5-HT2A receptor employed in radioligand binding assays, following a protocol already described [11].
Compound was assessed in concentration (0.1 nM–100 µM)-response curves either as agonist or as
antagonist of 1 µM serotonin (5-HT) response. 5-HT (0.1 nM–100 µM) and risperidone (0.01 nM–10 µM)
were used in these assays as reference agonist and antagonist, respectively.
2.2. Molecular Modeling
2.2.1. Receptor Structures
In cases where receptor X-ray structures were available, they were taken for molecular docking
after necessary mutations and preparation with Schrödinger software v. 2019-4 [14]: dopamine D2
receptor in complex with the antagonist risperidone (PDB ID: 6CM4 [15]), dopamine D3 receptor in
complex with the antagonist eticlopride (PDB ID: 3PBL [16]) and serotonin 5-HT2A receptor in complex
with the antagonist risperidone (PDB ID: 6A93 [17]. For dopamine D1 receptor, a previously reported
homology model [12] was used. For serotonin 5-HT7 receptor, a homology model was constructed with
Modeller v. 9.19 [18] using turkey β1 adrenoreceptor in complex with the antagonist cyanopindolol
(PDB ID: 2YCX [19]) as a template. All receptor structures were in inactive conformation, as D2AAK4
is or is expected to be their antagonist. MUSCLE (MUltiple Sequence Comparison by Log- Expectation)
was used for sequence alignment [20]. The sequence identity was 39% and sequence similarity was
58%. A population of 100 models was generated. The best model was selected based on Discrete
Optimized Protein Energy (DOPE) profiles obtained from Modeller v. 9.19 software.
2.2.2. Compound Preparation
D2AAK4 was modeled using LigPrep module [21] of Schrödinger suite of software, v. 2019-4
as previously reported [9,12,13,22,23]. In order to identify the protonation state, Epik module [24] of
Schrödinger suite of software, v. 2019-4 was applied.
2.2.3. Molecular Docking
Standard Precision (SP) approach of Glide [25] from Schrödinger release 2019-4 was used for
molecular docking of D2AAK4 to receptor models as reported previously [9,12,13,22,23]. 100 poses
were generated for each receptor. The final poses were selected based on Glide docking scores, and
visual inspection among the poses where the protonatable nitrogen atom of the ligand interacted
with conserved Asp 3.32 (number indicates Ballesteros-Weinstein nomenclature [26]). Visualization of
molecular modeling results was achieved with Maestro Release 2019.4 [14] and PyMol 2.0.4 [27] software.
2.2.4. Molecular Dynamics
The D2AAK4-receptor complexes were subjected to molecular dynamics with Desmond v.
3.0.3.1 [28] as reported previously [12,22]. In short, the complexes were immersed in POPC
(1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) membrane and hydrated, and ions were added
to neutralize protein charges and then to the concentration of 0.15 M NaCl. The complexes were
minimized and subjected to MD first in the NVT ensemble for 1 ns and then in NPT ensemble for 20 ns
with the restrictions on the protein backbone in each case. The production runs were performed in
NPT ensemble with no restrictions for 200 ns.
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2.3. Behavioral Studies
2.3.1. Animals
The experiments were carried out on naive Swiss male mice (Farm of Laboratory Animals,
Warszawa, Poland), 2 months old and weighing 20–30 g. All experiments were performed according
to the National Institute of Health Guidelines for the Care and Use of Laboratory Animals and the
European Community Council Directive for Care and Use of Laboratory Animals (2010/63/EU) and
approved by the local ethics committee (license 2/2015) as previously described [12]. Mice were
maintained under standard laboratory conditions and were adapted to the laboratory conditions as
described in our earlier work [12].
2.3.2. Drugs
D2AAK4 was purchased from Enamine (Z126202476), d-amphetamine sulphate and saline (0.9%
NaCl) from Sigma-Aldrich (St. Louis, MO, USA). D2AAK4 was suspended in 1% Tween 80 and
then diluted in saline (0.9%, vehicle) and d-amphetamine was dissolved in saline. The agents were
administered intraperitoneally (i.p.) as a 10 mL/kg volume. D2AAK4, d-amphetamine and vehicle
were freshly prepared before each experiment. Control groups received injections (vehicle) at the same
volume as well as by the same route of administration.
2.3.3. Motor Coordination Evaluated by Rotarod And Chimney Tests
Motor coordination has been assessed in mice using the rotarod test and the chimney test using
the same procedure as described in our earlier work [12]. Both tests were performed 60 min after
injection of D2AAK4 (100 mg/kg; i.p.) (n = 8) or vehicle (i.p.) (n = 8), using the same mice (i.e., after
rotarod test each mouse was placed to the chimney test). D2AAK1 was previously studied using the
same dose so we decided to select the dose of 100 mg/kg.
2.3.4. Spontaneous Locomotor Activity and Amphetamine-Induced Hyperactivity
The effect of D2AAK4 on mouse spontaneous locomotor activity was measured using an animal
activity meter Opto-Varimex-4 Auto-Track (Columbus Instruments, USA) kept in a sound-attenuated
experimental room. The Auto-Track System senses motion with a grid of infrared photocells monitoring
movements of animals placed in the transparent cages. More specifically, the arithmetic average for
distance (cm) traveled by a mouse (± SEM) measured for each group was analyzed and compared
to respective controls. Each mouse was placed for 30 min test to each cage 60 min after D2AAK4
(100 mg/kg; i.p.) (n = 7), amphetamine (5 mg/kg; s.c.) (n = 8) and vehicle (as a control) (n = 8)
administration. To determine whether D2AAK4 influences amphetamine-induced hyperactivity, each
animal was injected with D2AAK4 (100 mg/kg; i.p.) or vehicle (n = 7–8) and 30 min later mice were
treated with amphetamine (5 mg/kg; s.c.) or saline (n = 7–8). Then, 30 min later, spontaneous locomotor
activity was measured.
2.3.5. Passive Avoidance Task
The effect of D2AAK4 on long-term memory was evaluated in mice using the passive avoidance
(PA) task. The PA apparatus was described previously [12]. The PA procedure was also previously
described [12,29].
The experimental procedure involved evaluation of the memory consolidation after D2AAK4
(100 mg/kg; i.p.) or vehicle (control group) injections. Mice received D2AAK4 immediately after being
pretested on Day 1, and then they were retested (without injections) 24 h later. The changes in PA
performance were calculated as the difference between retention and training latencies (i.e., latency
index (IL)). More specifically, IL was calculated for each animal and presented as the ratio (as described
in [12,29]).
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2.3.6. Elevated Plus Maze (EPM) Procedure
The effect of D2AAK4 on mouse anxiety-like behavior was evaluated using the elevated plus
maze (EPM). The EPM apparatus was used as described previously [12]. The EPM procedure was
described in our previous papers [12,30]. The percentage (%) of time spent in the open arms and % of
entries into the open arms were calculated. Moreover, the number of entries into the closed arms was
recorded as the motor activity indicator of tested mice.
To determine D2AAK4 acute effect on anxiety-like behavior, the studied compound (100 mg/kg;
i.p.) (n = 8) or vehicle (i.p.) (n = 8) was injected 30 and 60 min before the EPM test.
2.3.7. Statistical Analysis
The statistical analyses were performed by two-way analysis of variance (ANOVA), followed by
the Tukey’s post hoc test to compare the pretreatment and treatment effects. One-way ANOVA and
t-test were used to compare differences between drugs and control group. Data were presented as
mean ± SEM. The confidence limit of p<0.05 was considered statistically significant.
3. Results
3.1. In Vitro Studies
3.1.1. Affinity Profile of D2AAK4 at Selected Targets
In a previous study, we carried out a structure-based virtual screening that resulted in the
identification of the compound D2AAK4, among other novel dopamine D2 receptor ligands. The
pharmacological profiling of D2AAK4 on a selected panel of dopamine D1-like (D1) and D2-like (D2,
D3), as well as serotonin (5-HT1A and 5-HT2A), receptors led to its characterization as a low-affinity
D2 receptor antagonist with moderate (3.67 times higher) affinity for 5-HT2A receptors [9] (Table 1),
being a 5-HT2A/D2 affinity ratio (Ki D2/Ki 5-HT2A) higher or equal to 1.12 (Meltzer’s ratio), considered
relevant for antipsychotic clinical efficacy and safety [31]. Here, we aimed at extending the in vitro
pharmacological affinity profiling of D2AAK4 to other receptors from the GPCR receptorome considered
relevant for clinical efficacy and/or side effects of antipsychotics, that is, serotonin 5-HT7, histamine H1
and muscarinic M1 receptors. The results from radioligand binding assays revealed the low affinity of
D2AAK4 for these three targets. Affinity values (pKi, Ki) of D2AAK4 at the selected panel of targets
(except for 5-HT1A, at which D2AAK4 did not show affinity (% inh. at 10 µM (mean ± SEM) = 9.7 ±
0.4%)) are given in Table 1. Examples of competition radioligand binding curves of D2AAK4 at the
different receptors profiled can be found in Supplementary Information (Figure S1).
Table 1. Experimental radioligand binding data for D2AAK4. Data are expressed as pKi (mean ± SEM)
of two (or three for 5-HT2A) independent experiments performed in duplicate. a Full displacement of
specific binding was not achieved at the maximum concentration assayed, so pKi value could be not
accurately estimated; maximum displacement achieved (at 100 µM) was 88% (5-HT7) and 91% (M1).
Clozapine reference affinity values at the indicated targets are shown for comparison. b Data taken
from PDSP Ki database (https://pdsp.unc.edu/databases/kidb.php). c Data taken from [32].
pKi
Comp. hD2 hD1 hD3 h5-HT1A h5-HT2A h5-HT7 hH1 hM1
D2AAK4 5.73 ± 0.09 5.60 ± 0.08 5.03 ± 0.08 - 6.31 ± 0.15 5.18 ± 0.24 a 5.41 ± 0.05 5.41 ± 0.11 a
Clozapine 6.81 b 6.72 b 6.38 b 6.91 b 8.10 b 6.83 c 8.93 b 8.03 b
3.1.2. D2AAK4 Is a D2/5-HT2A Antagonist
In a previous work, we characterized D2AAK4 as a D2 antagonist at the cAMP pathway
in vitro second messenger assays (inhibition of forskolin-stimulated cAMP production) carried out
in CHO-K1 cells stably transfected with human D2 receptor, where 10 µM D2AAK4 antagonized by
Biomolecules 2020, 10, 349 7 of 19
12% the response of 10 µM dopamine [9] (Supplementary Information, Table S1). The antagonist
efficacy of D2AAK4 at D2 receptors was confirmed in assays of cAMP production by constructing
concentration-response curves of the compound (Figure 2A). D2AAK4 antagonized dopamine response
in a concentration-dependent manner to an extent of 44% at 100 µM concentration, the maximal assayed
(Figure 2A and Supplementary Information, Table S1). IC50 of reference D2 antagonist haloperidol was
56 nM in these assays (pIC50 (mean ± SEM) = 7.25 ± 0.21) (Figure 2A).
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5-HT2A antagonism combined with weaker D2 antagonism is considered a key feature in the
pharmacological profile of atypical antipsychotics [33]. Therefore, the efficacy of D2AAK4 at human
5-HT2A receptors was further evaluated in functionally in vitro assays of second messenger (inositol
phosphate) production in CHO-K1 cells stably expressing the receptor. The compound was unable to
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promote IP signaling in the range of concentrations assayed (from 0.1 nM to 100 µM), indicating lack
of agonist efficacy, while the control agonist 5-HT efficiently stimulated IP signaling in dose-response
curves under the same conditions (data not shown). On the contrary, 1 µM 5-HT-stimulated IP
production was fully antagonized by D2AAK4 in concentration (0.1 nM–100 µM)-response curves,
showing an IC50 value of 714 nM consistent with its affinity value (Figure 2B and Supplementary
Information, Table S1). IC50 of reference 5-HT2A antagonist risperidone was 1.5 nM in these assays
(pIC50 (mean ± SEM) = 8.82 ± 0.05) (Figure 2B).
3.2. Molecular Modeling
3.2.1. Receptor Structures
As stated in Materials and Methods section, in the current study, we used previously published
model of D1 receptor [12] and X-ray structures of D2 [15], D3 [16] and 5-HT2A [17] receptors. Here, we
report a new homology model of 5-HT7 receptor. The Ramachandran plot of the final homology model
of serotonin 5-HT7 receptor is shown in Figure 3. The plot confirms the good quality of the constructed
homology model. The majority of residues lie in the allowed regions. The only outliers, not counting
proline and glycine residues, are Asn 226 and Ile 353 from extracellular loop regions. The model
was compared with the 5-HT7 receptor homology model in inactive conformation downloaded from
GPCRdb [34]. The RMSD (root-mean-square deviation) measured for complete models (including
loops) was 1.7 Å.
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residues are repres nted by circles. Glycines are shown as triangles. Prolines are shown as quares.
Two outliers are Asn 226 and Ile 35 , which are in extracellular loop regions.
3.2.2. Molecular Interactions of D2AAK4 with Aminergic G Protein-Coupled Receptors (GPCRs)
In order to study molecular interactions of D2AAK4 with dopaminergic and serotoninergic
receptors, molecular docking was performed. Figure 4 presents interactions of D2AAK4 with
dopamine D1, D2 and D3 receptors, while Figure 5 presents interactions with serotonin 5-HT2A and
5-HT7 receptors. The binding pose of D2AAK4 with all aminergic GPCRs studied is similar in all
receptors. The main anchoring point is the conserved Asp 3.32 [26] from the third transmembrane
helix, which forms an electrostatic interaction with the protonatable nitrogen atom of the ligand.
2-Oxo-2,3-dihydro-1H-benzimidazolyl moiety of D2AAK4 directs towards the receptor extracellular
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vestibule while 2-hydroxyphenyl group is located deeper in the receptor cavity. In the predicted
binding pose of D2AAK4 in the D2 receptor (Figure 4B), the amide group of D2AAK4 is in the (strained)
cis conformation. This conformation was found using flexible docking with Glide. It should be stressed
that in all the poses of D2AAK4 in the D2 receptor which involved the salt bridge with Asp 3.32
contained no steric clashes and were in general in accordance with the poses of this compound with
other receptors studied, the amide group was in cis configurations. The highest scored pose was selected
from them. In the case of interactions of D2AAK4 with dopamine D1 receptor (Figure 4A), the ligand
forms hydrogen bonds between its 2-oxo-2,3-dihydro-1H-benzimidazolyl group and side chains of
Lys 2.60 and Asp 7.35. In the case of dopamine D3 receptor, the 2-oxo-2,3-dihydro-1H-benzimidazolyl
group of the ligand forms a hydrogen bond with the main chain of Cys 181 from the second extracellular
loop (Figure 4C). Moreover, π–π stacking interactions between the 2-hydroxyphenyl group of the
ligand and Phe 6.52 and His 6.55 were found for this receptor.
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In case of interactions of it ser t in 5-HT2A r ceptor 2- xo-2,3-dihydro-
1H-benzimidazolyl group of the ligand forms a hydroge bond with th side chain of Asn 7.35
(Figure 5A). Furthermore, hydroxyl group of the ligand, as well as its a ide ato , form hydrogen
bonds with the main chain of Leu 229 from the second extracellular loop. For interactions of D2A K4
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with serotonin 5-HT7 receptor, a hydrogen bond between the 2-oxo-2,3-dihydro-1H-benzimidazolyl
group of the ligand and a side chain of Tyr 7.42 was found.
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3.2.3. Dynamic Aspects of Interactions of D2AAK4 with Aminergic GPCRs
200 ns molecular dynamics simulations were performed to study dynamic aspects of
ligand-receptor interactions. Ligand RMSD values plots are presented in Figure S2 in Supplementary
Information proving the correctness of the performed simulations and the stability of the systems.
In order to study D2AAK4 interactions with aminergic GPCRs during 200 ns molecular dynamics
simulations, histograms and summary plots of interactions were generated (Figure 6, Figure 7, Figures
S3 and S4). In case of all dopamine receptors studied, the contact (ionic or hydrogen bond) with the
conserved Asp 3.32 is maintained during 100% of simulations time. Hydrogen bond (or electrostatic or
water bridges) interactions between D2AAK4 and Lys 81 (2.60) of dopamine D1 receptor were found
during 81% of simulations. Water-mediated polar contacts were also identified between the ligand
and Ser 198 (5.43) and Asn 292 (6.55) of the receptor (67% and 39% of simulations time, respectively).
D2AAK4 was also involved with hydrophobic interactions with Trp 90 (first extracellular loop), Trp 99
(3.28), Val 100 (3.29) and Leu 190 (second extracellular loop).
Regarding interactions of D2AAK4 with dopamine D2 receptor, the ligand mediates hydrogen
bond interactions with Ser 193 (5.43) during 54% of simulations time and π–π stacking interactions with
Phe 390 (6.52) during 38% of simulations time. Hydrophobic interactions were also found between the
ligand and Trp 386 (6.48), Phe 389 (6.51), Phe 390 (6.52), His 393 (6.55) and Phe 411 (7.37).
In case of interactions of D2AAK4 with dopamine D3 receptor hydrogen bond between the ligand
and Ser 192 (5.43) was maintained during 48% of simulations time. Additional residues were involved
in hydrophobic interactions: Val 86 (2.60), Phe 345 (6.51), Phe 346 (6.52) and His 349 (6.55).
Studying dynamic aspects of interactions of D2AAK4 with serotonin 5-HT2A and 5-HT7 receptors
reveals that the electrostatic or hydrogen bond interaction with the conserved Asp 3.32 is maintained for
100% of simulations time for 5-HT2A receptor, while it is mainly a water bridge existing through about
30% of simulations time for 5-HT7 receptor. In the case of 5-HT2A receptor, additional water-mediated
polar contacts between the ligand and Ile 206 (4.56) or Ser 242 (5.46) [34] were formed during 58% and
30% of simulations time, respectively. In the case of 5-HT2A receptor, the following residues were
involved in hydrophobic interactions: Trp 139 (first extracellular loop), Val 156 (3.33), Leu 228 (second
extracellular loop), Phe 339 (6.51), Phe 340 (6.52) and Leu 362 (7.34).
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Figure 6. Molecular interactions of D2AAK4 with human dopamine D (A), D2 (B) and D3 (C) receptor
during 200 ns molecular dynamics simulations are shown as histograms of interactions. The stacked
bar charts are normalized over the course of the trajectory: for example, a value of 0.7 suggests that for
70% of the simulation time the specific interaction is maintained. Values over 1.0 are possible as some
protein residue may make multiple contacts of the same subtype with the ligand.
In the case of 5-HT7 receptor, D2AAK4 forms a hydrogen bond with Thr 167 (3.37) and Tyr 374
(7.42) during 36% and 30% of si ulations ti e, respectively. oreover, the ligand mediates cation π
interactions with Arg 350 (6.58). The residues involved in hydrophobic interactions are Phe 343 (6.51),
Phe 344 (6.52) and Arg 350 (6.58).
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3.3. Behavioral Studies
3.3.1. Effects of D2AAK4 on Motor Coordination, Spontaneous Locomotor Activity and
Amphetamine-Induced Hyperactivity in Mice
D2AAK4 at the studied dose (100 mg/kg, i.p.) does not impair mouse motor coordination as
evaluated in the rotarod and chimney tests (data not shown). The dose was selected based on the
previous results for D2AAK1 compound [12]. Lower doses have not been tested to reduce the number
of animals used, and this is a limitation to this actual study. However, in the future, we are planning to
repeat the same behavioral studies at different doses. The influence of D2AAK4 on the spontaneous
locomotor activity in mice is presented in Figure 8. One-way ANOVA analyses revealed significant
changes in the locomotor activity after D2AAK4 (100 mg/kg) and amphetamine (5 mg/kg) treatment in
mice (F(2,18) = 15.72, p = 0.0001). In addition, the post hoc Tukey’s test showed a statistically significant
increase in mice locomotor activity after amphetamine treatment (p < 0.01). We also determined the
effect of D2AAK4 on amphetamine-induced hyperactivity. Two-way ANOVA revealed significant
pretreatment (D2AAK4 or vehicle) x treatment (amphetamine or vehicle) interaction (F(1,26) = 6.14,
p = 0.0200), significant pretreatment effect (F(1,26) = 29.04, p < 0.0001) as well as treatment effect
(F(1,26) = 15.07, p = 0.0006). In addition, the post hoc Tukey’s test showed that administration of
amphetamine (p < 0.01, Figure 8) increased the locomotor activity of mice, while D2AAK4 did not
significantly change locomotor activity in mice when compared to control group. However, D2AAK4
coadministered with amphetamine decreased amphetamine-induced hyperactivity when compared to
the amphetamine-treated group (p < 0.001, Figure 8).
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statistically significant increase in the IL values (p < 0.0001) compared to respective-vehicle treated 
group. More specifically, the enhancement of the memory consolidation was observed after D2AAK4 
treatment. 
Figure 8. Acute effect of D2AAK4 on the ampheta ine-induced hyperactivity in mice. Appropriate
groups of mice receiv d D2AAK4 ((10 mg/kg; i. (n = 7)), amphetamine (5 m /kg, (n = 8 ; s.c.),
D2AAK4 (100 mg/kg) coadministered with 5 mg/kg amphetamine (n vehicle (n = 8, indicated as
0). Data are presented as mean ± SEM of the distance traveled (cm) by mouse recorde f r 30 i . The
post hoc Tukey’s test indicates: ** p < 0.01 amphetamine vs. the vehicle-treated group and ˆˆˆ p < 0.001
D2AAK4 coadministered with amphetamine vs. amphetamine-treated group.
3.3.2. Effect of Acute Administration of D2AA 4 on e ory Consolidation in Mice
The D2AAK4 effect on memory consolidation was evaluated during the retention trial of the
PA task (Figure 9). T-test revealed that the acute administration of D2AAK4 (100 mg/kg; i.p.)
induces a statistically significant increase in the IL values (p < 0.0001) compared to respective-vehicle
treated group. More specifically, the enhancement of the memory consolidation was observed after
D2AAK4 treatment.
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Figure 9. cute effect of 2 4 on e ory consolidation in ice evaluated in passive avoidance
(P ) test. Appropriate groups of mice were injected D2 AK4 (100 mg/kg (n = 8); i.p.) and vehicle
((n = 8, indicated as 0); i.p.) on Day 1 immediately after the PA test, and 24 h later (i.e., on Day 2), these
ice ere retested as previously described in [12]. Data are presented as ean ± SE . The results
fro the t-test analyses indicate: *** p < 0.0001 when compared with the vehicle-treated group.
3.3.3. Anxiety-Like Effects after D2AAK4 Treatment in Mice
To evaluate the influence of the acute administration of D2AAK4 on anxiety-like responses in mice,
EPM tests were conducted. The statistical analysis (t-test) of the results for the activity of D2AAK4 (100
mg/kg) on anxiety-like responses indicated significant influence on % of the time spent in the open
arms (p < 0.0001) (Figure 10) evaluated 30 and 60 min after D2AAK4 administration and % of the open
arm entries (p = 0.0272 and p = 0.0092 after 30 and 60 min, respectively) (Figure 10). In particular, the
decrease in both % of the time spent in the open arms and the open arm entries indicates anxiogenic
activity of D2AAK4 (Figure 10).
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treat ent using elevated plus aze (EP ) test. Percentage (%) of open arm entries (A,C) and % of
ti e spent in the open ar s (B,D) recorded 30 (A,B) and 60 (C, ) inutes after 100 g/kg 2 AK4
injection ((n = 8) and vehicle (n = 8, indicated as 0); i.p). Data ar presented as mean ± SEM. The
esults from the t-test analyses indicate the anxiogenic activity elicited by D2AAK4 30 and 60 min after
treat ent *** p < 0. 01 for time spent in the open arms (both 30 and 60 min) and for open ar entries
(30 in: * p = 0.0272 and 60 min: ** p = .0092).
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4. Discussion
The aim of the presented study was a detailed in vitro, in silico and in vivo characterization of the
virtual hit D2AAK4 identified in structure-based virtual screening [9]. Such a characterization of the
hit compound is useful prior to its optimization to find a lead molecule for a potential antipsychotic.
D2AAK4 is a multitarget compound with moderate affinity to dopamine D1, D2, D3 and serotonin
5-HT2A and 5-HT7 receptors. In particular, D2AAK4 is a low-affinity D2 receptor antagonist with
moderate (3.67 times higher) affinity for 5-HT2A receptors [9]; that is, with a 5-HT2A/D2 affinity ratio
(Ki D2/Ki 5-HT2A) higher than 1.12 (Meltzer’s ratio) [31], making it a compound with an atypical
antipsychotic profile. Atypical antipsychotics such as ziprasidone and paliperidone (9-OH-risperidone,
the primary metabolite of risperidone approved by US Food and Drug Administration (FDA) in 2006)
show 5-HT2A/D2 affinity ratios of ~5.60 and 2.16, respectively. Moreover, the affinity of D2AAK4 to
serotonin 5-HT7 receptor could be beneficial to treat cognitive symptoms of schizophrenia [35]. It also
has low affinity to other GPCRs that have been pointed out as off-targets within the antipsychotic
pharmacology profile, i.e., histamine H1 receptor and muscarinic M1 receptor. Histamine H1 receptors
antagonism is responsible for weight gain associated with second-generation antipsychotics [36] as
well as with sedation [37]. M1 muscarinic receptor blockade causes memory impairment [38] while
activation or positive allosteric modulation of this receptor may be a way to treat cognitive disturbances
in schizophrenia [39].
As a multitarget compound, D2AAK4 could be of interest for further optimization of its
pharmacological profile in the search of a potential lead compound with atypical antipsychotic
properties. The multitarget approach to drug discovery is currently a hot topic in medicinal
chemistry. It turned out that in the case of diseases with complex pathomechanisms, such as
neurodegenerative diseases, cancer or schizophrenia, a single-target approach is not promising.
Modulation of several receptors with one drug molecule also has pharmacokinetic advantages and
allows one to avoid drug–drug interactions and to minimize side effects. For instance, the promising
multitarget antipsychotic brexpiprazole exerts partial agonism at dopamine D2, D3 and serotonin
5-HT1A receptors combined with antagonism at 5-HT2A, 5-HT2B and 5-HT7 receptors [40]. This drug
was approved by the FDA in 2015 for schizophrenia and as adjunctive treatment in major depression,
and by the European Medicines Agency (EMA) in 2018 for schizophrenia treatment. Side effects of
brexpiprazole include weight gain, akathisia, upper respiratory tract infections, somnolence, headache,
and nasopharyngitis (as reviewed in [8]).
Importantly, D2AAK4 is an antagonist of both dopamine D2 receptor and serotonin 5-HT2A
receptor, which is beneficial for its antipsychotic profile. All antipsychotics currently present on the
market are dopamine D2 receptor antagonists or partial/biased agonists. Thus, it seems that modulation
of this receptor is necessary to treat positive symptoms of the disease. Blockade of dopamine D2 receptor
relates to a number of side effects, including motor disorders from the extrapyramidal system [41]
and endocrine system dysregulation [42]. In the case of D2AAK4 with atypical profile, the risk of
extrapyramidal disorders would be reduced [43], while a weaker blockade of dopaminergic receptors
combined with stronger 5-HT2A blockade is thought to explain the more limited elevation of prolactin
plasma levels by second-generation antipsychotics as a group over first-generation antipsychotics [44].
Furthermore, antagonism of 5-HT2A receptor is considered advantageous for the treatment of negative
symptoms of schizophrenia [45].
A part of the studies presented here is molecular modeling of interactions of D2AAK4 with
respective aminergic GPCRs. In the case of serotonin 5-HT7 receptor, first, we constructed a homology
model of this protein. Our model is an addition to previously published homology models of serotonin
5-HT7 receptor [46–49] and is in general accordance with them. Molecular interactions of D2AAK4
with the studied aminergic GPCRs are typical for ligands with a protonatable nitrogen atom interacting
with the conserved Asp 3.32 as the main anchoring point [50]. Other identified residues, in particular
Phe 6.51, Phe 6.52, His 6.55 and the residues from the extracellular loop are in agreement with
our earlier results for D2AAK1 [12] and its derivatives [13,23]. The identified interactions include
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residues (Ser 5.43, Ser 5.46, His 6.55) that have been previously identified as determinants for the
specific multitarget binding profile of atypical antipsychotics such as clozapine and olanzapine [11,51].
Moreover, targeted chemical modulation of ligand interaction with residue His 6.55 at D2 receptors led
to the development of a signaling-pathway-specific antagonist/partial agonism ligand [52]. Overall,
the multitarget interactions here described for D2AAK4 provide a robust structural support for rational
further developments on this virtual hit.
The compound D2AAK4 turned out to be active in behavioral studies at a dose of 100 mg/kg.
It decreased amphetamine-induced hyperactivity in mice, which is a measure of its antipsychotic
potential [53]. Moreover, it improved memory consolidation in mice in the passive avoidance test. The
PA is based on the acquisition, storage and retention of aversive Pavlovian conditioning involving
short- and long-term memory processes. There is evidence showing that the antipsychotics generally
showed impairment of the PA response in rodents [54]. In particular, clozapine, olanzapine, lurasidone
and asenapine presented impaired PA performance, so it would be desirable to find drug candidates
that did not impair memory performance in early screening tests. In addition, risperidone impaired
PA performance, but only at doses that were 10-fold greater than those active in the test of inhibition of
hyperlocomotion induced by MK-801 predictive of antipsychotic-like activity, while aripiprazole did
not impair PA performance but was poorly active in the MK-801 test [54]. On the other hand, multiple
studies have shown that the second-generation antipsychotics (SGAs) improved set-shifting ability
(cognitive flexibility) (as reviewed in [55]). For instance, clozapine and olanzapine presented positive
effects in attention and verbal fluency with improvements in executive functioning and delayed recall,
while olanzapine also showed improvement in selective attention, vigilance, verbal learning and
memory (as reviewed in [55]).
Current antipsychotics are efficacious at treating positive symptoms, and it is considered that
atypical antipsychotics should be generally preferred over first-generation drugs in the treatment of
schizophrenia with prominent negative symptoms, and they also appear to be associated with lower
cognitive impairment and better functional outcomes [56–58]. In particular, first-generation drugs
often even worsen the cognitive abilities of the patients, which is one of the reasons for lack of patient
compliance with drug regimes. However, the efficacy of atypical antipsychotics against cognitive
impairment and negative symptoms is at best limited, according to the most recent effectiveness
reviews and pharmacotherapy guidelines [59]. For example, results from the Clinical Antipsychotic
Trials of Intervention Effectiveness (CATIE) study (as reviewed in [55]), which included chronic
schizophrenia patients, indicated that the improvement in cognition was found to be small [60],
with questionable clinical significance [61]. Thus, it is urgently needed to elaborate an antipsychotic
able to cure cognitive and negative symptoms as well, as these are still considered important unmet
clinical needs. In this context, cariprazine showed efficacy in schizophrenia patients with predominant
negative symptoms [62], having been proposed as a good therapeutic option for this population [63].
The EPM test indicated that D2AAK4 has anxiogenic properties in this mice model, which contrasts
with the previously published compound D2AAK1 [12]. It was shown that atypical antipsychotics
including aripiprazole, quetiapine, olanzapine, and risperidone are helpful in addressing a range of
anxiety and depressive symptoms in individuals with schizophrenia [64]. In this regard, optimization
of D2AAK4 will have aims—among others—of obtaining compound with anxiolytic characteristics.
Prior to this task, the molecular target responsible for the anxiogenic effect needs to be identified, and
then molecular modeling approaches may be used to minimize the interactions of D2AAK4 derivatives
with this receptor.
5. Conclusions
In summary, D2AAK4 is a promising virtual hit, confirmed in vitro and active in vivo, which is a
starting point to generate a lead molecule for a novel antipsychotic. Attempts will be made to further
balance its multitarget profile as well as to obtain analogs with anxiolytic, not anxiogenic, properties.
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1. Stępnicki, P.; Kondej, M.; Kaczor, A.A. Current Concepts and Treatments of Schizophrenia. Molecules 2018,
23, 2087. [CrossRef] [PubMed]
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence,
prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories,
1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018, 392, 1789–1858.
3. Benes, F.M. The GABA system in schizophrenia: Cells, molecules and microcircuitry. Schizophr. Res. 2015,
167, 1–3. [CrossRef] [PubMed]
4. De Bartolomeis, A.; Buonaguro, E.F.; Iasevoli, F. Serotonin-glutamate and serotonin-dopamine reciprocal
interactions as putative molecular targets for novel antipsychotic treatments: From receptor heterodimers to
postsynaptic scaffolding and effector proteins. Psychopharmacology 2013, 225, 1–19. [CrossRef]
5. Laruelle, M. Schizophrenia: From dopaminergic to glutamatergic interventions. Curr. Opin. Pharmacol. 2014,
14, 97–102. [CrossRef]
6. Kane, J.M. Treatment strategies to prevent relapse and encourage remission. J. Clin. Psychiatry 2007, 68, 27–30.
7. Aringhieri, S.; Carli, M.; Kolachalam, S.; Verdesca, V.; Cini, E.; Rossi, M.; McCormick, P.J.; Corsini, G.U.;
Maggio, R.; Scarselli, M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical
differences. Pharmacol. Ther. 2018, 192, 20–41. [CrossRef]
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